2P2IHUNTER: A tool for filtering orthosteric protein-protein interaction modulators via a dedicated support vector machine

Journal of the Royal Society Interface

Volumn 11, Issue 90, 2014, Pages

  Hamon, Véronique ^a   Bourgeas, Raphael ^a   Ducrot, Pierre ^b   Theret, Isabelle ^b   Xuereb, Laura ^b   Basse, Marie Jeanne ^a   Brunel, Jean Michel ^a   Combes, Sebastien ^a   Morelli, Xavier ^a   Roche, Philippe ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Drug design; Filtering algorithm; Focused chemical library; Protein protein interactions; Small molecule inhibitors; Support vector machine

Indexed keywords

BIOASSAY; CHEMICAL COMPOUNDS; LIBRARIES; MOLECULES; PROTEINS; THROUGHPUT;

CHEMICAL LIBRARIES; DRUG DESIGN; FILTERING ALGORITHM; PROTEIN-PROTEIN INTERACTIONS; SMALL MOLECULE INHIBITOR;

SUPPORT VECTOR MACHINES;

2P2IHUNTER; ACCURACY; ARTICLE; BIOASSAY; COMPUTER PROGRAM; DATA BASE; HIGH THROUGHPUT SCREENING; MACHINE LEARNING; MOLECULAR LIBRARY; PROTEIN PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; CHEMICAL DATABASE; DRUG DESIGN; FILTERING ALGORITHM; FOCUSED CHEMICAL LIBRARY; METHODOLOGY; PROTEIN ANALYSIS; PROTEIN-PROTEIN INTERACTIONS; SMALL MOLECULE INHIBITORS; VALIDATION STUDY;

DRUG DESIGN; FILTERING ALGORITHM; FOCUSED CHEMICAL LIBRARY; PROTEIN-PROTEIN INTERACTIONS; SMALL MOLECULE INHIBITORS; SUPPORT VECTOR MACHINE;

DATABASES, CHEMICAL; PROTEIN INTERACTION MAPPING; SMALL MOLECULE LIBRARIES; SUPPORT VECTOR MACHINES;

EID: 84889646329     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2013.0860     Document Type: Article

References (69)

1. Wells J, McClendon C. 2007 Reaching for highhanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009. (doi:10.1038/nature06526)
2. Fry DC. 2012 Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partner. Curr. Pharm. Des. 18, 4679-4684. (doi:10.2174/138161212802651634)
3. Morelli X, Hupp T. 2012 Searching for the Holy Grail; protein-protein interaction analysis and modulation. EMBO Rep. 13, 877-879. (doi:10.1038/embor. 2012.137)
4. Mullard A. 2012 Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 11, 173-175. (doi:10.1038/nrd3680)
5. Morelli X, Bourgeas R, Roche P. 2011 Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr. Opin. Chem. Biol. 15, 475-481. (doi:10.1016/j.cbpa. 2011.05.024)
6. Wilson CG, Arkin MR. 2011 Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied. Curr. Top Microbiol. Immunol. 348, 25-59. (doi:10.1007/82-2010-93)
7. Khoury K, Dömling A. 2012 P53 mdm2 inhibitors. Curr. Pharm. Des. 18, 4668-4678. (doi:10.2174/138161212802651580)
8. Cesa LC, Patury S, Komiyama T, Ahmad A, Zuiderweg ER, Gestwicki JE. 2013 Inhibitors of difficult protein-protein interactions identified by high-throughput screening of multiprotein complexes. ACS Chem. Biol. 8, 1988-1997 (doi:10.1021/cb400356m)
9. Arkin MR, Whitty A. 2009 The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr. Opin. Chem. Biol. 13, 284-290. (doi:10.1016/j.cbpa.2009.05.125)
10. Azzarito V, Long K, Murphy NS, Wilson AJ. 2013 Inhibition of a-helix-mediated protein-protein interactions using designed molecules. Nat. Chem. 5, 161-173. (doi:10.1038/nchem.1568)
11. Fletcher S, Hamilton AD. 2006 Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J. R. Soc. Interface 3, 215-233. (doi:10.1098/rsif.2006.0115)
12. Wells JA. 1995 Structural and functional epitopes in the growth hormone receptor complex. Nat. Biotechnol. 13, 647-651. (doi:10.1038/nbt0795-647)
13. Blazer LL, Neubig RR. 2009 Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology 34, 126-141. (doi:10.1038/npp.2008.151)
14. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. 2011 Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin. Emerg. Drugs 16, 59-70. (doi:10.1517/14728214.2010.515210)
15. Fry D. 2011 Small-molecule inhibitors of protein-protein interactions. In Nutley (eds L Vassilev, D Fry), pp. 184. New Jersey: Springer.
16. Koes DR, Camacho CJ. 2011 Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure. Bioinformatics 28, 784-791. (doi:10.1093/bioinformatics/btr717)
17. Vu BT, Vassilev L. 2011 Small-molecule inhibitors of the p53-MDM2 interaction. Curr. Top. Microbiol. Immunol. 348, 151-172. (doi:10.1007/82-2010- 110)
18. Sakuma Y, Tsunezumi J, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, Miyagi Y. 2011 ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol. Rep. 25, 661-667. (doi:10.3892/or.2010.1123)
19. Higueruelo AP, Jubb H, Blundell TL. 2013 Protein-protein interactions as druggable targets: recent technological advances. Curr. Opin. Pharmacol. 13, 791-796. (doi:10.1016/j.coph.2013.05.009)
20. Higueruelo AP, Jubb H, Blundell TL. 2013 TIMBAL v2: update of a database holding small molecules modulating protein-protein interactions. Database 2013, bat039. (doi:10.1093/database/bat039)
21. Fuller JC, Burgoyne NJ, Jackson RM. 2009 Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 14, 155-161. (doi:10.1016/j.drudis.2008.10.009)
22. Sugaya N, Ikeda K. 2009 Assessing the druggability of protein-protein interactions by a supervised machine-learning method. BMC Bioinform. 10, 263. (doi:10.1186/1471-2105-10-263)
23. Bourgeas R, Basse M-J, Morelli X, Roche P. 2010 Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. PLoS ONE 5, e9598. (doi:10.1371/journal.pone.0009598)
24. Geppert T, Hoy B, Wessler S, Schneider G. 2011 Context-based identification of protein-protein interfaces and 'hot-spot' residues. Chem. Biol. 18, 344-353. (doi:10.1016/j.chembiol.2011.01.005)
25. Wanner J, Fry DC, Peng Z, Roberts J. 2011 Druggability assessment of protein-protein interfaces. Future Med. Chem. 3, 2021-2038. (doi:10.4155/fmc.11. 156)
26. Sugaya N, Furuya T. 2011 Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions. BMC Bioinform. 12, 50. (doi:10.1186/1471-2105-12-50)
27. Kozakov D et al. 2011 Structural conservation of druggable hot spots in protein-protein interfaces. Proc. Natl Acad. Sci. USA 108, 13 528-13 533. (doi:10.1073/pnas.1101835108)
28. Koes DR, Camacho CJ. 2012 PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res. 40, W387-W392. (doi:10.1093/nar/gks336)
29. Metz A, Ciglia E, Gohlke H. 2012 Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application. Curr. Pharm. Des. 18, 4630-4647. (doi:10.2174/138161212802651553)
30. Thangudu RR, Bryant SH, Panchenko AR, Madej T. 2012 Modulating protein-protein interactions with small molecules: the importance of binding hotspots. J. Mol. Biol. 415, 443-453. (doi:10.1016/j.jmb.2011.12.026)
31. Ulucan O, Eyrisch S, Helms V. 2012 Druggability of dynamic protein-protein interfaces. Curr. Pharm. Des. 18, 4599-4606. (doi:10.2174/138161 212802651652)
32. Johnson DK, Karanicolas J. 2013 Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface. PLoS Comput. Biol. 9, e1002951. (doi:10.1371/journal.pcbi.1002951)
33. Hamon V, Morelli X. 2013 Druggability of protein-protein interactions. In Understanding and exploiting protein-protein interactions as drug targets (ed. G. Zinzalla), pp. 18-31. London, UK: Future Science Ltd. (doi:10.4155/ 9781909453463)
34. Hajduk PJ, Huth JR, Tse C. 2005 Predicting protein druggability. Drug Discov. Today 10, 1675-1682. (doi:10.1016/S1359-6446(05)03624-X)
35. Edfeldt FN, Folmer RH, Breeze AL. 2011 Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov. Today 16, 284-287. (doi:10.1016/j.drudis.2011.02.002)
36. Valkov E, Sharpe T, Marsh M, Greive S, Hyvönen M. 2012 Targeting protein-protein interactions and fragment-based drug discovery. Top. Curr. Chem. 317, 145-179.
37. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, Blundell TL. 2012 Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys. 45, 1-44. (doi:10.1017/S0033583512000108)
38. Scott DE, Ehebauer MT, Pukala T, Marsh M, Blundell TL, Venkitaraman AR, Abell C, Hyvönen M. 2013 Using a fragment-based approach to target protein-protein interactions. Chembiochem 14, 332-342. (doi:10.1002/cbic. 201200521)
39. Wu B, Zhang Z, Noberini R, Barile E, Giulianotti M, Pinilla C, Houghten R, Pasquale E, Pellecchia M. 2013 HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem. Biol. 20, 19-33. (doi:10.1016/j.chembiol.2012.10.015)
40. Barker A, Kettle JG, Nowak T, Pease JE. 2013 Expanding medicinal chemistry space. Drug Discov. Today 18, 298-304. (doi:10.1016/j.drudis.2012.10. 008)
41. Fry D et al. 2013 Design of libraries targeting protein-protein interfaces. ChemMedChem 8, 726-732. (doi:10.1002/cmdc.201200540)
42. Bunnage ME. 2011 Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335-339. (doi:10.1038/nchembio.581)
43. Pagliaro L, Felding J, Audouze K, Nielsen SJ, Terry RB, Krog-Jensen C, Butcher S. 2004 Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr. Opin. Chem. Biol. 8, 442-449. (doi:10.1016/j.cbpa.2004.06.006)
44. Higueruelo AP, Schreyer A, Bickerton GRJ, Pitt WR, Groom CR, Blundell TL. 2009 Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug Des. 74, 457-467. (doi:10.1111/j.1747-0285.2009.00889.x)
45. Neugebauer A, Hartmann RW, Klein CD. 2007 Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J. Med. Chem. 50, 4665-4668. (doi:10.1021/jm070533j)
46. Reynes C et al. 2010 Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput. Biol. 6, e1000695. (doi:10.1371/journal.pcbi.1000695)
47. Sperandio O, Reynès C, Camproux A, Villoutreix B. 2010 Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov. Today 15, 220-229. (doi:10.1016/j.drudis.2009.11.007)
48. Villoutreix BO, Labbé CM, Lagorce D, Laconde G, Sperandio O. 2012 A leap into the chemical space of protein-protein interaction inhibitors. Curr. Pharm. Des. 18, 4648-4667. (doi:10.2174/138161212802651571)
49. Labbé CM, Laconde G, Kuenemann MA, Villoutreix BO, Sperandio O. 2013 iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov. Today 18, 958-968. (doi:10.1016/j.drudis.2013.05.003)
50. Buchwald P. 2010 Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 62, 724-731. (doi:10.1002/iub.383)
51. Basse MJ, Betzi S, Bourgeas R, Bouzidi S, Chetrit B, Hamon V, Morelli X, Roche P. 2013 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 41, D824-D827. (doi:10.1093/nar/gks1002)
52. Venkatesan K et al. 2009 An empirical framework for binary interactome mapping. Nat. Methods 6, 83-90. (doi:10.1038/nmeth.1280)
53. Stumpf M, Thorne T, de Silva E, Stewart R, An H, Lappe M, Wiuf C. 2008 Estimating the size of the human interactome. Proc. Natl Acad. Sci. USA 105, 6959-6964. (doi:10.1073/pnas.0708078105)
54. Li Q, Wang Y, Bryant SH. 2009 A novel method for mining highly imbalanced high-throughput screening data in PubChem. Bioinformatics 25, 3310-3316. (doi:10.1093/bioinformatics/btp589)
55. Hamon V, Brunel JM, Combes S, Basse MJ, Roche P, Morelli X. 2013 2P2Ichem: focused chemical libraries dedicated to orthosteric modulation of protein-protein interactions. MedChemComm 4, 797-809. (doi:10.1039/c3md00018d)
56. Tsao DHH et al. 2006 Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg. Med. Chem. 14, 7953-7961. (doi:10.1016/j.bmc.2006.07.050)
57. Tsiang M et al. 2012 New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J. Biol. Chem. 287, 21 189-21 203. (doi:10.1074/jbc.M112. 347534)
58. Christ F et al. 2010 Rational design of smallmolecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 6, 442-448. (doi:10.1038/nchembio.370)
59. Cossu F et al. 2009 Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochem. Biophys. Res. Commun. 378, 162-167. (doi:10.1016/j.bbrc.2008.10.139)
60. Wang Y et al. 2010 An overview of the PubChem BioAssay resource. Nucleic Acids Res. 38, D255-D266. (doi:10.1093/nar/gkp965)
61. Xie XQ. 2010 Exploiting PubChem for virtual screening. Expert Opin. Drug Discov. 5, 1205-1220. (doi:10.1517/17460441.2010.524924)
62. Marson CM. 2011 New and unusual scaffolds in medicinal chemistry. Chem. Soc. Rev. 40, 5514-5533. (doi:10.1039/c1cs15119c)
63. Lievens S, Eyckerman S, Lemmens I, Tavernier J. 2010 Large-scale protein interactome mapping: strategies and opportunities. Expert Rev. Proteomics 7, 679-690. (doi:10.1586/epr.10.30)
64. HTStec. 2012 Future Directions of HTS Trends. Cambridge, UK: HTStec. See http://www.htstec.com/.
65. Lipinski C, Lombardo F, Dominy B, Feeney P. 2001 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26. (doi:10.1016/S0169-409X(00)00129-0)
66. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 2002 Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623. (doi:10.1021/jm020017n)
67. Pearlman RS, Smith KM. 1999 Metric validation and the receptor-relevant subspace concept. J. Chem. Info. Comput. Sci. 39, 28-35. (doi:10.1021/ci980137x)
68. Cortes C, Vapnik V. 1995 Support-vector networks. Mach. Learn. 20, 273-297. (doi:10.1007/BF00994018)
69. Josse J. 2008 FactoMineR: an R package for multivariate analysis. J. Stat. Softw. 25, 1-18.